Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 8/20 | 0.36 |
| ▸ | CES1 | P23141 | 5/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510184 | 0.98 | CES2 (0.44) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL18799580 | 0.98 | CES2 (0.44) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL19509962 | 0.96 | CES2 (0.46) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL18612496 | 0.96 | CES2 (0.46) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL18791600 | 0.96 | DGAT1 (0.40) | CES2MEN1KMT2ADGAT1FAAH | |
| SCHEMBL18799587 | 0.94 | CES2 (0.40) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL19509954 | 0.92 | DGAT1 (0.38) | CES2MEN1KMT2ADGAT1FAAH | |
| SCHEMBL19509956 | 0.89 | CES2 (0.43) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL19728842 | 0.89 | CES2 (0.43) | CES2MEN1KMT2AMAPTATM | |
| SCHEMBL18791624 | 0.88 | DGAT1 (0.38) | CES2MEN1KMT2ADGAT1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | St. Chuan University (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20170305920-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SI CHUAN UNIVERSITY (CN) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305920-A1 | 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF | DPYD, TYMP, WEE1 | CES2 3108/4885MEN1 1370/4885KMT2A 3206/4885 |
| US-10266537-B2 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | DPYD, TYMP, WEE1 | CES2 3108/4885MEN1 1370/4885KMT2A 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.